NASDAQ:ENSC Ensysce Biosciences (ENSC) Stock Price, News & Analysis $0.37 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.36▼$0.3850-Day Range$0.37▼$0.6452-Week Range$0.35▼$2.06Volume208,455 shsAverage Volume1.24 million shsMarket Capitalization$2.84 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Ensysce Biosciences alerts: Email Address Ensysce Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,771.7% Upside$7.00 Price TargetShort InterestHealthy0.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.48) to ($1.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.57 out of 5 stars 3.5 Analyst's Opinion Consensus RatingEnsysce Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnsysce Biosciences has received no research coverage in the past 90 days.Read more about Ensysce Biosciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.21% of the float of Ensysce Biosciences has been sold short.Short Interest Ratio / Days to CoverEnsysce Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ensysce Biosciences has recently decreased by 92.65%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnsysce Biosciences does not currently pay a dividend.Dividend GrowthEnsysce Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENSC. Previous Next 1.1 News and Social Media Coverage Search Interest8 people have searched for ENSC on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows3 people have added Ensysce Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ensysce Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders52.70% of the stock of Ensysce Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.63% of the stock of Ensysce Biosciences is held by institutions.Read more about Ensysce Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ensysce Biosciences are expected to grow in the coming year, from ($1.48) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ensysce Biosciences is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ensysce Biosciences is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnsysce Biosciences has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ensysce Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Ensysce Biosciences Stock (NASDAQ:ENSC)Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.Read More ENSC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENSC Stock News HeadlinesAugust 27, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Announces IRB Approval for Key MPAR StudyAugust 27, 2024 | theglobeandmail.comBiotech Steals The Show Following $14 Million Grant AnnouncementSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 27, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose ProtectionAugust 27, 2024 | msn.comENSC Treatment Gets Substantial GrantAugust 23, 2024 | globenewswire.comDiamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)August 15, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Reports Second Quarter 2024 Financial ResultsAugust 15, 2024 | msn.comENSC Furthers Important Drug ResearchSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 8, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Provides Key Themes Following IASP 2024 SymposiumAugust 3, 2024 | finance.yahoo.comEnsysce Biosciences, Inc. (NASDAQ:ENSC): Are Analysts Optimistic?July 24, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Provides Mid-Year 2024 UpdateJune 24, 2024 | investorplace.comENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024May 20, 2024 | finance.yahoo.comSector Update: Health Care Stocks Softer Late AfternoonMay 14, 2024 | finance.yahoo.comEnsysce Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 13, 2024 | msn.comENSC: Quarterly Report Highlights ProgressApril 25, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge MagazineApril 25, 2024 | finance.yahoo.comEnsysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge MagazineSee More Headlines Receive ENSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENSC CUSIPN/A CIK1716947 Webensysce.com Phone858-263-4196FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+1,771.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,610,000.00 Net Margins-784.35% Pretax Margin-784.42% Return on Equity-834.40% Return on Assets-327.00% Debt Debt-to-Equity RatioN/A Current Ratio1.88 Quick Ratio1.88 Sales & Book Value Annual Sales$2.23 million Price / Sales1.27 Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book2.20Miscellaneous Outstanding Shares7,585,000Free Float3,588,000Market Cap$2.84 million OptionableNot Optionable Beta0.87 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. D. Lynn Kirkpatrick Ph.D. (Age 67)President, CEO & Director Comp: $414.77kMr. David C. Humphrey CPA (Age 55)CFO, Secretary & Treasurer Comp: $348.15kMr. Geoffrey Birkett (Age 61)Chief Commercial Officer Comp: $322kDr. Jeffrey Millard Ph.d. (Age 48)Chief Operating Officer Dr. William K. Schmidt Ph.D. (Age 73)Chairman of Clinical Advisory Board & Chief Medical Officer Dr. Linda Pestano Ph.D. (Age 54)Chief Development Officer More ExecutivesKey CompetitorsVirax Biolabs GroupNASDAQ:VRAXPurple BiotechNASDAQ:PPBTForte BiosciencesNASDAQ:FBRXPHAXIAM TherapeuticsNASDAQ:PHXMAgile TherapeuticsNASDAQ:AGRXView All Competitors ENSC Stock Analysis - Frequently Asked Questions How have ENSC shares performed this year? Ensysce Biosciences' stock was trading at $1.06 at the start of the year. Since then, ENSC stock has decreased by 64.7% and is now trading at $0.3740. View the best growth stocks for 2024 here. How were Ensysce Biosciences' earnings last quarter? Ensysce Biosciences, Inc. (NASDAQ:ENSC) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.17. The business had revenue of $0.18 million for the quarter, compared to analysts' expectations of $0.30 million. Ensysce Biosciences had a negative trailing twelve-month return on equity of 834.40% and a negative net margin of 784.35%. When did Ensysce Biosciences' stock split? Ensysce Biosciences shares reverse split on the morning of Friday, March 31st 2023. The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Ensysce Biosciences? Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENSC) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ensysce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
